drugset / Trial / NCT02298985

Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients

NCT02298985

RandomizedSingle-groupTriple-blindTreatment

Summary

Schizophrenia is still remained one of the disabling disorders despite progress in treatment of mental disturbances. Ten to thirty percents of patients have a little or no benefit from treatment with all kinds of antipsychotics using adequate dosages and duration. Treatment of these patients has remained a persistent public health problem since medication-resistant patients are often highly symptomatic. Curcumin is one of the main curcuminoids isolated from this perennial herb. It possesses a variety of pharmacological activities, including anti-inflammatory, antiproliferative, antioxidant, and neuroprotective effects and crosses the blood-brain barrier. The purpose of our suggested study is to examine the efficacy of curcumin as add-on the conventional antipsychotic psychopharmacotherapy in chronic schizophrenia patients.

Timeline

Start
2015-01
Primary completion
2017-01
Completion
2017-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Curcumin Small molecule 3000 mg Oral

Indications